BRAF and colorectal carcinoma: We further revealed that the combination of MEK2 inhibition by lycorine and BRAF inhibition by vemurafenib resulted in enhanced anti-cancer activity in CRC, providing evidence of the potential of targeted combination regimens for personalized therapy.